Alluvi, formerly BI 4744, offers a significant advance in weight control treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive efficacy in clinical studies, https://alluvi-healthcare950249.blogs-service.com/74500270/alluvi-a-comprehensive-dive-into-the-drug-s-prospects